Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Personalized DBS for OCD Guided by Stereoencephalography Mapping

NCT: NCT06347978 · ACTIVE_NOT_RECRUITING

NCT IDNCT06347978
StatusACTIVE_NOT_RECRUITING
Start Date2024-05-24
Completion2028-05
SponsorAndrew Moses Lee, MD, PhD (OTHER)
First posted
Last updated

Brief Summary

This is a double-blinded, randomized, crossover study design for SEEG-guided 4-lead DBS for treatment-refractory OCD, followed by open label stimulation for an additional 6 months. The study will be conducted in 3 stages: Stage 1 will consist of SEEG brain mapping and optimization of stimulation parameters. Stage 2 will consist of 4-lead DBS surgery with bilateral IPGs and further optimization of stimulation parameters. Stage 3 will be randomized, crossover treatment, followed by open label treatment.

Frequently Asked Questions

What is Personalized DBS for OCD Guided by Stereoencephalography Mapping?

Personalized DBS for OCD Guided by Stereoencephalography Mapping is a clinical trial registered under NCT06347978. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT06347978?

The current status of NCT06347978 (Personalized DBS for OCD Guided by Stereoencephalography Mapping) is: ACTIVE_NOT_RECRUITING.

When did Personalized DBS for OCD Guided by Stereoencephalography Mapping start?

Personalized DBS for OCD Guided by Stereoencephalography Mapping started on 2024-05-24.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑